{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.7","upperLimit":"49.0","value":"37.3"},{"groupId":"OG001","lowerLimit":"21.9","upperLimit":"43.1","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"221"}],"units":"Participants"}],"description":"Measured in months from randomization to last contact or death. Primary analysis was restricted to the eligible uterine carcinosarcoma cohort.","dispersionType":"95% Confidence Interval","groups":[{"description":"Paclitaxel 175 mg/m2 IV over 3 hours Day 1 Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles","id":"OG000","title":"Regimen I- Uterine Carcinsarcoma Subjects"},{"description":"Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6","id":"OG001","title":"Regimen II - Uterine Carcinsarcoma Subjects"}],"paramType":"MEDIAN","populationDescription":"All eligible patients","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 115 months.","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}